ICPT - Intercept's Drug Will Be First To NASH Market But Many Challenges Remain
Intercept Pharmaceuticals (ICPT) recently reported interim results from its phase 3 REGENERATE study. It noted that it had met on one co-primary endpoint, but failed on another. The company will be able to file for FDA and EMA approval, but a few issues associated with the drug may not allow it to reach blockbuster status. Thus, the stock has sold off the last few days. I believe that the stock might recover on other upcoming news of regulatory filings, but the market opportunity is not as clear as it once used to be.